slides · global inventory
Consultants Gambit
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 39,432
Current window 7,591-7,620
Pages 1,315
Rows per page 30
Arc
7,591-7,620 of 39,432
07
The chart compares 'Facilities' vs 'Operating / procedure rooms' across four ownership categories: Management-owned, Hospital-owned, 100% physician-owned multi-specialty, and 100% physician-owned single-specialty.L.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizations · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
08
The chart uses bubble size to represent total procedure volume. Two distinct regions are highlighted: emerging specialties (high growth, low penetration) and mature specialties (low growth, high penetration).L.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizations · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
09
The slide uses a combination of a qualitative list of strategic options and a quantitative stacked bar chart to illustrate market behavior regarding hospital partnerships.L.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizations · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
10
The slide uses two horizontal bar charts to contrast partnership drivers with operational pain points.L.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizations · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
11
The slide uses a green color palette consistent with L.E.K. branding. The content is structured as a list of failure modes.L.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizations · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
12
The slide uses a process-oriented framework to map analytical inputs to strategic questions.L.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizations · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next Steps1 hit
13
L.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizationsL.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizations · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next Steps1 hit
01
Perspectives on US Healthcare Inflation Insights from L.E.K. ConsultingPerspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Situation & Context1 hit
02
Perspectives on US Healthcare Inflation Insights from L.E.K. ConsultingPerspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Situation & Context1 hit
03
The chart uses a dual-line plot to show the divergence between healthcare and general inflation, with a shaded region for the Great Recession.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
04
Data shows hospital-related services as the primary driver of recent healthcare inflation.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
06
The slide uses a dual-axis chart combining line graphs for cumulative change and bar charts for 12-month percentage change.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Evidence & Proof1 hit
08
The chart highlights a divergence between healthcare inflation and general inflation, with a specific forecast range for healthcare.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
09
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
11
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Solution & Approach1 hit
01
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
02
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
03
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
04
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
05
The table is segmented into three thematic blocks: demographics, economic indicators, and healthcare market metrics.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
06
Uses a PEST framework (Policy, Economy, Society, Technology) to structure the market analysis.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
07
The slide uses a comparative bar chart structure to contrast high growth in China (29% CAGR) against stable growth in the U.S. (3% CAGR).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
08
The slide uses a honeycomb layout to group regulatory initiatives. Color coding indicates the nature of the policy (R&D, Registration, Pricing/Market Access, Commercialization).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
09
The slide uses stacked bar charts to show the composition of clinical trials by phase (I, II, III) for China and the US.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
10
Data refers to enterprises above designated annual revenue size (>20M RMB). Exchange rate 6.25 used.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
11
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
12
The slide combines quantitative survey data (N=101) with qualitative expert quotes to contextualize the market sentiment.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
13
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
14
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
15
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit